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INTRODUCTION
The role of unrelated-donor bone marrow transplanta-
tion (UD BMT) in the management of acute myeloid
leukemia (AML) is uncertain [1,2]. We previously reported a
cohort of 18 pediatric and adult patients with AML in
remission (13 in ﬁrst clinical remission [CR1] and 5 in CR2)
who, after a median follow-up of 28 months, had 70% and
74% event-free and overall survival, respectively [3].
Because of these encouraging preliminary results, we have
continued to perform UD BMT in patients with AML in
CR2 as our treatment of choice for patients lacking a sibling
donor, but we have also performed transplantations in
selected patients in CR1 who are at high risk of relapse.
The major alternative treatment for patients with
relapsed AML is high-dose therapy and a stem cell autograft
using cells harvested in CR1 or CR2. This procedure is
associated with a low mortality rate but a high chance of
relapse. The long-term functional status of survivors is
good. Stem cell autograft is also used for AML in CR1,
although its value in high-risk patients is debatable [4].
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ABSTRACT
The outcome for 39 patients with acute myeloid leukemia (AML) in remission who had CAMPATH 1M
T cell–depleted unrelated donor bone marrow transplantations (BMTs) is described. Conditioning was mainly with
cyclophosphamide (120 mg/kg) and total body irradiation (TBI) (14.4 Gy), but 5 patients received busulfan in place
of TBI and 200 mg/kg cyclophosphamide. All patients received cyclosporin, and short-course methotrexate was
given to recipients of mismatched grafts. The patient population was predominantly pediatric (median age, 10 years),
but one third of the patients was aged 15 years or above. Twenty-five patients were in second complete remission
(CR2), and 14 had high-risk CR1 disease (primarily failed remission induction or antecedent myelodysplastic syn-
drome, often with complex cytogenetic abnormalities). Both recipient and donor were cytomegalovirus seronegative
in 15 of 37 cases (38%); 51% of patients were matched for HLA class I and II. Grade II to IV acute graft-versus-host
disease (GVHD) occurred in 24% of patients; chronic GVHD occurred in 5 of 31 evaluable patients (16%), 4 extensive
and 1 limited. Relapse occurred in 5 cases (13%); 1 of these 5 patients survives, 24 months after a second unrelated
donor transplantation. Two of these relapses were associated with secondary graft failure (incidence rate, 5%). All
patients engrafted primarily. Severe viral infection was the major transplant-associated complication, with
12 episodes in 9 patients, 5 of them lethal. Twenty-five patients survive at a median follow-up of 44 months (range,
2-102 months), with estimated actuarial overall and disease-free survival rates at 44 months of 61% (SE 8%) and
57% (SE 8%), respectively. Nineteen patients are more than 2 years post-BMT and may be cured. The functional
status of long-term survivors is excellent, with 19 of 21 patients who survive 6 months or more in full-time employ-
ment or full-time students. These encouraging results suggest that in patients lacking a sibling donor, unrelated
donor BMT for AML in remission achieves survival figures as good as or better than those reported on patients
with autologous stem cell transplantation, and that T-cell depletion of grafts is associated with a low relapse rate
and an excellent functional status. However, only a randomized study comparing unrelated donor BMT and auto-
grafting will resolve which of these treatment strategies is better for patients with AML.
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There are no published randomized studies comparing
autograft and UD BMT in AML, and patient selection is
clearly very important in comparing series of different treat-
ment modalities.
In this report, we describe the medium- to long-term
outcome for 39 patients who received unrelated donor trans-
plants for AML in remission. We document the transplanta-
tion-associated morbidities and emphasize long-term func-
tional outcome.
PATIENTS AND METHODS
Patients and Exclusion Criteria
The patient population (Table 1) described represents
39 consecutive patients with AML in remission who had
allogeneic transplantations using marrow from an unre-
lated donor from June 1991 to October 1999. This was a
mixed pediatric and adult population, with 12 patients aged
15 years or more. All but 3 patients receiving transplants
were initially treated on UK Medical Research Council
AML protocols; the remainder were treated on German
(BFM) protocols. The majority (25) were in CR2; 14 patients
were in CR1. For the patients in CR2, the median time from
relapse to transplantation was 3 months (range, 2-12 months).
The reasons for transplantation in the 14 patients in CR1
are shown in Table 2. Two further patients were having UD
BMT for AML as their second allogeneic transplantation
and were excluded.
For the purposes of this study, remission was deﬁned as
no clinical evidence of leukemia, recovering peripheral
blood counts, and a marrow aspirate containing <5% blasts.
Because many of these patients received transplants shortly
after count recovery, there was no requirement for the
remission state to be maintained for 1 month. Patients not
in remission at the time of transplantation are excluded from
analysis. The term “failed remission induction” means that
at day 28 after initial induction chemotherapy, the marrow
aspirate contained >20% blasts.
Conditioning Regimen
All patients received intravenous CAMPATH 1G (2.5-
10 mg twice a day, depending on weight) on days –9 to –5.
Thirty-four patients received cyclophosphamide 60 mg/kg
on days –6 and –5 and 14.4 Gy total body irradiation in
8 fractions on days –3 to 0, as previously described [5]. Four
patients did not receive any irradiation, 1 because the
patient had received prior extensive irradiation and 3
because they were less than 3 years of age. All of these
patients received 50 mg/kg cyclophosphamide for 4 days
and 16 mg/kg (3) or 20 mg/kg (2) busulfan also given over
4 days (one of these had additional melphalan 140 mg/m2).
One patient admitted to the intensive care unit during con-
ditioning had 75% of the total body irradiation replaced by
busulfan (8 mg/kg).
Graft-Versus-Host Disease Prophylaxis
Graft-versus-host disease (GVHD) prophylaxis and
grading of acute and chronic GVHD have been previously
Table 1. Pretransplantation Characteristics of 39 Recipients of Unrelated
Donor Transplants for Acute Myeloid Leukemia*
Age, y 10 (1-40)
0-9 16
10-19 17
20-29 2
30-39 3
≥40 1
Sex, M/F 22/17
Donor and recipient CMV seronegative 15 (38%)
Harvested mononuclear cell dose,  108/kg 5.1 (1.7-43.9)
Ex vivo T-cell depletion, % 98.5 (80.0-100)†
Matching
Class I and II matched 20
Class I mismatch 18
Class II mismatch 1
Disease status
CR1 14
CR2 25
Female donor 16
Sex matching, recipient/donor
Male/male 15
Male/female 7
Female/male 8
Female/female 9
FAB type
M0 1
M1 6
M2 9
M3 4
M4/5 12
M6 2
M7 1
Mixed lineage 1
Secondary AML 1
Diagnostic material not available 2
Duration of CR1 in CR2 patients, mo 18 (1-46)
Time from diagnosis to transplantation 6.5 (4.5-9)
in CR1 patients, mo
*Data are median (range) or n. CMV indicates cytomegalovirus;
CR, clinical remission; FAB, French-American-British; AML, acute
myeloid leukemia.
†n = 37 transplantations.
Table 2. Major Adverse Prognostic Factors in 14 Patients Receiving Unrelated-
Donor Bone Marrow Transplants for Acute Myeloid Leukemia in First Clinical
Remission
Factor n
Failed remission induction 5*
Antecedent myelodysplastic syndrome 3
Infantile leukemia with 11q23 abnormality 2†
Prolonged severe hypoplasia following consolidation chemotherapy 1
High white blood cell count at diagnosis 1
Secondary leukemia with complex cytogenetic abnormalities 1
Reason not known 1
*Two of the 5 patients also had complex cytogenetic abnormalities,
1 had a high presenting white blood cell count, and 1 had antecedent
anaplastic large cell lymphoma.
†One of the 2 patients also had a high white blood cell count and
central nervous system involvement.
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described [3]. Thirty-seven marrow transplants were T-cell
depleted with CAMPATH antibodies (35 with 1M and 2
with 1G) and human AB serum to provide complement.
Two patients who had low harvested cell doses had intra-
venous CAMPATH 1G (10 mg twice a day) from day 0 to 4
to provide in vivo T-cell depletion. Cyclosporin A was
started the day before transplantation, continued for 3 to
6 months, and then gradually tapered if there was no
GVHD. All patients receiving mismatched marrow trans-
plants also received 3 doses of intravenous methotrexate
(15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6).
Histocompatibility, Immunogenetics, and Donor
Selection
Searches were conducted of the British Bone Marrow
Registry and Anthony Nolan Bone Marrow Trust and, in
certain cases, European and American registries.
HLA class I typing was performed using standard sero-
logical techniques before 1993 and by medium resolution
polymerase chain reaction (PCR)-sequence–speciﬁc primer
after 1993. HLA-A and -B mismatches were preferred to
-DR and -DQ mismatches. Matching for HLA-C has more
recently become a selection criterion and was retrospec-
tively performed where donor and recipient DNA were
available. Typing for HLA-DRB1 and -DQB1 was per-
formed with restriction fragment length polymorphism
analysis and more recently with PCR amplification of
sequence-specific primers. HLA-DP matching was not a
selection criterion. Cytomegalovirus (CMV) status was an
important factor in donor selection, but the ability to
achieve a high cell dose using a large male donor was also
paramount in selection.
Supportive Care
Supportive care has been described in detail previously
[3,6], but there have been some changes in practice. CMV
surveillance for the ﬁrst 18 patients was with 3 bronchoalve-
olar lavages at days 30, 60, and 90, but since then has been
with twice-per-week CMV PCR and early antigen ﬂuores-
cence testing in parallel for the first 3 to 6 months after
transplantation. Antigenemia at any level or 2 consecutive
positive PCRs were considered indications for treatment
with ganciclovir.
Since 1997, prophylactic itraconazole has been given as
a suspension, with levels monitored to maintain concentra-
tions >0.25 mg/L.
Follow-up and Statistics
For the ﬁrst 2 months, the majority of the clinical fol-
low-up was at the Bristol BMT unit; after that, follow-up
was at 3-month intervals for the first 2 years. Since 1998,
bone marrow aspirates have been performed only when
abnormalities in the peripheral counts or other clinical fea-
tures suggested failure of engraftment or leukemic relapse.
Before that time, aspirates were performed at 1, 2, 3, 6, 9,
12, 18, and 24 months and yearly thereafter.
Kaplan-Meier estimates of survival (as of December 1,
1999) were calculated and subgroups compared using the
log-rank test. Cox proportional hazards regression analysis
was used to assess the effects of 2 prognostic variables simul-
taneously. The 2-tailed Fisher exact test was used to com-
pare the incidence of acute and chronic GVHD between
matched and unmatched patients.
RESULTS
HLA Matching
Of the 39 transplants, 20 were fully matched at all loci
tested (Table 1). Only 1 patient was class II (single DR
locus) mismatched with the donor; the rest (18 patients)
were class I mismatched. Of these 18 mismatched trans-
plants, 11 were mismatched at 1 locus (6 A, 1 B, and 4 C),
6 at 2 loci (B and C in 4; A and C in 2) and 1 at 3 loci (B and
2 C). Of the 11 single class I mismatches, 4 were not tested
for HLA-C (stored DNA was not available) and may be mis-
matched at that locus also.
Engraftment
One patient died of infection at day 3; 38 transplanta-
tions are evaluable for myeloid and megakaryocytic engraft-
ment. Of evaluable patients, 100% had neutrophil engraft-
ment (>0.5  109/L for 3 days) at a median of 15 days
posttransplantation. Only 2 patients engrafted >3 weeks
posttransplantation (23 and 57 days, respectively).
Megakaryocytic recovery was less prompt. Four patients
(11%) did not achieve a platelet count of >50  109/L, and
the median time to that level was 27 days. However, of the
34 transplantations with megakaryocytic recovery, 5 took
>60 days.
Two previously described patients (5%) suffered sec-
ondary graft failure. Both were managed with the infusion
of autologous stem cells. Both patients relapsed; 1 died of
leukemia and 1 had a second UD transplantation and is alive
in remission 28 months after his second transplantation.
Both were donor-recipient mismatches.
Graft-Versus-Host Disease
Clinically significant (grade II to IV) acute GVHD
occurred in 9 of 38 evaluable transplantations (24%), with
minor (grade I) GVHD occurring in an additional 5 patients
Figure 1. Probability of overall survival in 39 patients who received
unrelated donor bone marrow transplants for acute myeloid leukemia
in remission.
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(13%). No patient had grade III to IV GVHD. Of the 9
transplantations with signiﬁcant GVHD, 7 were mismatched
with the donor, compared with 12 mismatches in the
29 transplantations without signiﬁcant GVHD (P = .124).
Chronic GVHD was diagnosed in 5 patients (4 exten-
sive, 1 limited). Of these 5 patients, 4 were mismatched with
the donor (P = .340). One patient has bronchiolitis obliter-
ans that has responded well to cyclosporin and steroid ther-
apy. There was no association between cell dose and acute
or chronic GVHD (data not shown).
Relapse
Two patients relapsed following secondary graft failure
and autologous rescue. Three additional patients relapsed
(total incidence of 13%). Four of the 5 patients died of their
disease; 1 is alive and in remission 28 months after a second
UD transplantation. The median follow-up of survivors is
44 months. The majority of relapses occur in the ﬁrst 2 years
after allografts for AML [7]; all but 5 survivors in this study are
2 or more years posttransplantation. The last relapse in our
series occurred 13 months after transplantation. Of the
5 patients who relapsed, 3 had no GVHD and 2 had moderate
acute GVHD. Numbers are insufﬁcient to analyze whether
GVHD protected against relapse. Of the 5 patients who
relapsed, 3 were matched and 2 mismatched with the donor.
Infection
Twenty viral infections were documented in 14 patients
(6 CMV, 5 respiratory syncytial virus [RSV], 3 adenovirus, 1
aciclovir-resistant herpes simplex, 2 influenza A, 1 parain-
ﬂuenza 3, 1 human herpes virus 6, and 1 rotavirus).
Three of the RSV infections were associated with lethal
pneumonitis and 1 with graft failure. Two of the 6 CMV infec-
tions were associated with lethal pneumonitis and 2 with
CMV disease (1 with associated thrombotic thrombocytopenic
purpura [TTP]); 2 cases represented minor episodes of reacti-
vation. Of the other viral infections, the following were severe:
1 adenovirus, 1 resistant herpes simplex, 1 inﬂuenza B (with
subsequent bronchiolitis obliterans), 1 parainﬂuenza 3, and
1 very severe persistent rotavirus. In total, 12 of 20 infections
were considered serious or life-threatening.
Two patients died of bacterial infections (both Enterobac-
ter cloaceae). Two further patients survived life-threatening
infections. One had severe typhilitis (no organism found), and
the other required admission to the intensive care unit with
Escherichia coli septicemia, acute renal impairment, and septic
shock. Of the 7 patients who died of infection, the median
time that death occurred was 4 months post-BMT (range,
3 days to 13 months). There was no association between the
development of grade II to IV acute or extensive chronic
GVHD and dying of infection (data not shown).
Other Transplantation-Associated Morbidity
One patient who developed TTP responded to plasma-
pheresis and cessation of cyclosporin but died of recurrent
TTP 9 months posttransplantation. This patient had severe
(life-threatening) hemorrhagic cystitis that resolved sponta-
neously at day 100 post-BMT. Polyoma virus was isolated
from the urine only shortly before the cystitis resolved, and
it is uncertain if the virus played a major role in the patho-
genesis of the cystitis.
One patient has developed polycythemia with a hemat-
ocrit >60% and an increased red cell mass, the cause of which
is currently unknown; it is being treated by venesection alone.
An erythropoietin-producing tumor is being sought.
Another long-term survivor (>5 years) has a mild car-
diomyopathy with minimally reduced ejection fraction on
echocardiography. This patient is on lifelong enalapril and
digoxin but has a normal exercise tolerance.
One patient developed an immune thrombocytopenia
and another a Coomb’s positive autoimmune hemolytic ane-
mia. Both responded to corticosteroids.
Death
Fourteen patients have died, from 3 days to 15 months
posttransplantation. Seven patients died of infection
(5 viral and 2 bacterial) and 5 of relapsed disease. Of the
remaining patients, 1 had multiple life-threatening prob-
lems but died of TTP, and another died in the intensive
care unit with respiratory distress syndrome, but no organ-
ism was identified.
Survival and Functional Status
Twenty-five patients survive (all in remission) at a
median of 44 months (range, 2-102 months), with the esti-
mated actuarial overall survival rate at 44 months being 61%
(SE 8%) and the disease-free survival being 57% (SE 8%)
(Figure 1). Of the 21 patients who survived more than
6 months post-BMT, 19 are in full-time work or school
(Table 3). One patient’s quality of life was severely compro-
mised by bronchiolitis obliterans and bilateral aseptic necro-
sis of the femoral heads, but after hip replacements is now
able to attend school part-time.
Overall survival rate is 57% ± 13% for patients in CR1
and 62% ± 11% for patients in CR2 (not signiﬁcant [NS]).
The 100-day survival rate was 94%. Of the 14 patients with
pediatric leukemia (diagnosed before 16 years of age) who
underwent transplantations in CR2 who had a ﬁrst remission
duration of 12 months or more, 10 survive with an estimated
actuarial survival of 71% at a median follow-up of 44
months. Only 2 of these 14 patients have relapsed.
We examined a number of possible prognostic factors to
see if they correlated with outcome (Table 4). Age did not
have an adverse effect on outcome. In fact, patients aged 15
years or more had a survival of 71% ± 14% compared with
56% ± 10% of those aged <15 years (NS). Donor-recipient
mismatch, sex mismatch, recipient and donor sex, cell dose,
and degree of T-cell depletion did not signiﬁcantly inﬂuence
outcome, but this may be due to small numbers. There was
a strong trend on univariate analysis that CMV-seronegative
transplants did better (P = .062, log-rank test) and that
patients who underwent transplantations before 1996 did
better (P = .088). It was difﬁcult to assess the importance of
these 2 factors because a greater proportion of CMV-
seropositive transplantations were performed since 1996.
When both factors were considered in a Cox proportional
hazards model, neither was statistically signiﬁcant.
We also examined whether the duration of CR1 affected
the outcome in the 24 patients who underwent transplanta-
tions in CR2. Survival in the group with a CR1 duration
>18 months was better than that in the group with a shorter
remission duration (74% versus 47%; P = .119, log-rank test).
D.I. Marks et al.
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DISCUSSION
In this report, we show that more than half and up to two
thirds of patients with AML in remission can achieve long-
term disease-free survival with a T cell–depleted UD trans-
plant. T-cell depletion of the graft was effective in preventing
acute and chronic GVHD, but the relapse rate was low.
There are 2 possible explanations for the latter finding.
Either a graft-versus-leukemia (GVL) effect is relatively
unimportant in curing this disease or there is a signiﬁcant
GVL effect even with moderate T-cell depletion [8]. The
rates of complete response of relapsed AML to donor white
cell infusions are low [9,10]. However, acute GVHD did
signiﬁcantly reduce the incidence of relapse in 1 study [11]
(from 42% to 26%), and the risk of relapse appears to be
greater (relative risk 2.58) after identical twin transplants [12].
Survivors in our series have an excellent performance
status, so the major potential long-term difference between
UD BMT and autografting (a poor performance status due
to chronic GVHD) appears to have been minimized. How-
ever, the place of UD transplantation in the management of
a patient with AML is far from certain. Variable patient
selection criteria make comparisons of series of different
treatment modalities unreliable. Its role in ﬁrst and second
complete remission and possibly its role in children versus
adults requires separate discussion.
The treatment options for a patient with AML in CR2
without a sibling donor are relatively straightforward.
Options include an autograft using stem cells taken in CR1
or CR2 or allogeneic BMT using an unrelated or haploiden-
tical donor. The outcome of haploidentical BMT is the least
widely documented [13], and many will reserve it for the
patient with no well-matched unrelated donor or when
there is a need to proceed quickly because the second remis-
sion is not likely to last long.
The estimated survival in the 25 patients with AML in
CR2 is 62% ± 11%. There are few published series with
which to compare these results (Table 5) [14-16]. In general,
our results compare favorably with the reported literature,
and our incidence of acute and chronic GVHD is as low as
any published series. We did not record data from the excel-
lent series from St Jude’s Hospital [17], because it contains
too few patients with AML in remission to make a reliable
comparison. Of note, the International Bone Marrow
Transplant Registry (IBMTR) has data from 477 patients
with AML in CR2 with a median age of 24 years who have a
32% probability of survival at 3 years (M. Horowitz, MD,
personal communication). The major causes of death in
these patients were relapse and infection.
Our results also appear to be considerably better than
most of those reported for autografting in CR2. Most series
Table 3. Major Clinical Outcomes of 39 Unrelated Donor-Transplantations
for Acute Myeloid Leukemia*
Days to 0.5  109/L neutrophils† 15 (12-57)
Days to 50  109/L platelets‡ 27 (12-365)
Acute GVHD§
Grade I 5 (13)
Grade II to IV 9 (24)
Chronic GVHD
Limited 1 (3)
Extensive 4 (10)
Total 5 (13)
Relapse 5 (13)
Current functional status¶
Working full time 5
Full-time education 14
Part-time work or education 1
Functional status not known 1
*Data are median (range), n (%), or n.
†38 transplantations were evaluable.
‡38 transplantations were evaluable; 4 did not achieve this platelet
count (1 due to thrombotic thrombocytopenic purpura).
§38 transplantations were evaluable; 1 patient died at day 3.
31 patients survived 120 days.
¶22 patients survive more than 6 months posttransplantation but
one is too young to attend school and was not eligible for this analysis.
Table 4. Association Between Prognostic Factors and Actuarial Survival *
Prognostic factor Survival, %† SE, %
Matching
Matched 74 10
Mismatched 51 12
P .320
Cell dose
Cell dose < 3.7  108/kg 67 14
Cell dose > 3.7 108/kg 58 10
P .702
Age
<15 y 56 10
≥15 y 72 11
P .170
Sex of recipient
Male 64 11
Female 57 12
P .550
Sex of donor
Male 57 11
Female 67 12
P .970
CMV status
Seronegative 79 11
Positive donor and/or recipient 49 11
P .062
T-cell depletion
<98.5% 65 12
>98.5% 56 12
P .583
Date of transplantation
Before 1996 75 11
After 1/1/1996 50 12
P .088
Patients in CR2
CR1 duration >18 months 74 13
CR1 duration <18 months 47 18
P .119
First or second CR
CR1 57 13
CR2 62 11
P .840
*By univariate analysis. CMV indicates cytomegalovirus; CR, clini-
cal remission.
†Kaplan-Meier estimates at 20 months.
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report 25% to 35% disease-free survival [4,18,19], with only
the series of Gorin et al. [20] and Linker et al. [21] reporting
better results (41% and 52%, respectively), possibly related
to purging or different conditioning regimens. In children,
excellent results have been reported with autografting in
CR2 when the duration of CR1 was >12 months, with >50%
disease-free survival [22]. However, the same subset in our
cohort had a 71% survival rate.
The decision of whether a patient with high-risk AML
in CR1 should undergo transplantation is complex. The fac-
tors to be considered are the following: the chance of cure
with chemotherapy alone, the chance of cure associated with
transplantation in CR1, and the chance of salvage after
relapse. The chance of salvage is, in turn, related to the
chance of achieving a second remission and the chance of
cure with a transplantation in CR2. Each of these factors
will be considered in detail.
The outcome of high-risk AML in CR1 with chemo-
therapy alone is poor, with only 24% surviving in CR1 in
the recent Medical Research Council (MRC) AMLX study
[4]. The “poor-risk” group comprised patients with failed
remission induction (>20% blasts after course 1), abnormali-
ties of chromosomes 5 and 7, and complex karyotypic
abnormalities. It should be noted that not all of our patients
fell into one of these adverse groups.
For patients with AML in first relapse, the chance of
obtaining CR2 ranges from 33% to 69% [22-24]. Webb [22]
recently reviewed the outcome in a large national trial of chil-
dren with AML who relapsed. Of 87 children who received
intensive chemotherapy, 61 achieved a second remission. The
overall survival rate was 24% at 3 years but was 44% in the
group who achieved CR2. Of 61 children, 44 received a stem
cell transplants (22 auto, 12 UD, and 12 sibling graft). The
following factors predicted a poor outcome: a ﬁrst remission
duration of <1 year, adverse cytogenetics, a high lactate
dehydrogenase level, and increasing age. The chance of suc-
cessful salvage therapy in an adult with relapsed AML may
be lower. In the recent MRC AMLX study, 101 patients
relapsed in the chemotherapy arm; although 59% achieved
CR2, only 13% survived [4]. It is also likely that the chance
of achieving a CR2 in a patient with poor-risk AML is lower
than the chance for all relapsed patients.
In general, poor-risk features for AML treated with
chemotherapy are also poor risks for high-dose therapy. It is
difficult to speculate what the outcome of the 14 patients
with AML in CR1 would have been with other treatment
modalities, because their high-risk factors were quite hetero-
geneous. In this article, we report a 57% disease-free survival
rate for patients with AML in CR1 with a median follow-up
of 43 months for the survivors. This compares with the
IBMTR ﬁgures of a 40% 4-year survival rate in 380 patients
with AML in CR1 with a median age of 24 years (M.
Horowitz, personal communication). However, the detailed
risk factors of these IBMTR patients have not been analyzed.
Our results are satisfactory given the high-risk nature of the
patients, but what are the alternatives? The major ones seem
to be offering chemotherapy only with a plan for high-dose
therapy (autografting or UD BMT) in CR2, autografting in
CR1, or performing a haploidentical transplantation in CR2.
Some of the justiﬁcation for performing UD BMT for
AML in CR1 comes from the results of sibling allografting.
Recent series of sibling allografts of AML in CR1 have
yielded excellent results, with the French and Memorial Sloan
Kettering groups reporting 71% to 77% disease-free survival
in adults [8,25] and Michel et al. [26] reporting 71% disease-
free survival in children. In these series [8,25,26], there are
both low relapse rates (3% to 23%) and low transplant-
related mortality rates. Biologically randomized studies indi-
cate that for AML in CR1, allografting is superior to chemo-
therapy and autografting in adults and children [18,27] and
the availability of a matched sibling appears to be a good
prognostic factor [28,29], but allografting has not been found
to be beneﬁcial in all studies [30]. It can be reasonably con-
cluded that no therapy is better than sibling allografting for
this group of patients, so if the transplantation-related mor-
tality and morbidity of UD BMT can be made equivalent to
sibling grafts, this too would become a mainstream therapy.
However, there are few data demonstrating the effec-
tiveness of allografting for high-risk CR1 AML. In a large
European study [31], 29% of the poor-risk group (abnormal
5 or 7 or 11q or hypodiploidy) survive after allograft com-
pared with 21% in the autograft group (NS). In contrast, 20
patients with poor-risk AML in CR1 received autografts in
the MRC AMLX study, and 9 (45%) survive [4]. However,
these numbers are too small to draw deﬁnite conclusions.
Our results also raise a number of other important
issues. The major scope for improving these results would
seem to be better prevention and treatment of infection,
particularly with viruses [32]. Viral infection may, in part, be
the price of T-cell depletion and its slow associated immune
reconstitution. CMV disease was a significant problem in
this group of patients, but CMV deaths have become less
common in our UD transplantation patients with intensive
molecular surveillance and aggressive therapy of early viral
reactivation (D.I.M., unpublished data). Infection with com-
munity-acquired respiratory viruses such as RSV is a signiﬁcant
Table 5. Results of Unrelated-Donor Bone Marrow Transplantation for Acute Myeloid Leukemia*
GVHD, %
Source [reference] n Age, y DFS, % Acute Chronic
Minneapolis [10] 15 9 33 at 2 years III-IV: 26 54
Seattle [11] 13 9 46 83 to 98† 60 to 69†
Vienna [12] 19 32 40 at 17 months I-IV: 85 —
IBMTR 477 24 32 at 3 years Not analyzed
*Some series included patients who were in third clinical remission or not in remission, in contrast to our study. The IBMTR data include only
patients in CR2. DFS indicates disease-free survival; GVHD, graft-versus-host disease; IBMTR, International Bone Marrow Transplant Registry.
†Higher number refers to mismatched patients.
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problem [33], and there is currently little evidence that rib-
avirin and RSV-speciﬁc immunoglobulin affect outcome in
infected BMT patients.
In summary, T cell–depleted UD BMT can offer a high
chance of survival for patients with AML in remission. At
present, we believe our results are sufﬁciently good for it to
be considered standard therapy in a young patient with
AML in CR2 with an HLA-A, -B, -C, -DR, and -DQ
matched unrelated donor. In addition, it can result in pro-
longed disease-free survival in older (>35 years) patients
with AML in CR2 and patients in CR2 with mismatched
donors. It should be noted that in our report we demon-
strated a trend toward an association between GVHD and
mismatching, but low numbers may have precluded a statis-
tically signiﬁcant association. Our results of UD transplan-
tation for CR1 are provocative and suggest that this
approach may be warranted for selected high-risk patients.
Future improvements in results will come mainly from
reducing the toxicity of the procedure, particularly by ﬁnd-
ing better ways of treating and preventing infection.
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